Repeatability of Peripapillary OCT Angiography in Neurodegenerative Disease.

Abstract

Purpose

To assess the repeatability of peripapillary OCT angiography (OCTA) in those with Alzheimer disease (AD), mild cognitive impairment (MCI), Parkinson disease (PD), or normal cognition.

Design

Cross-sectional.

Participants

Patients with a clinical diagnosis of AD, MCI, PD, or normal cognition were imaged. Those with glaucoma, diabetes mellitus, vitreoretinal pathology, and poor-quality images were excluded.

Methods

Each eligible eye of each participant underwent 2 OCTA 4.5 × 4.5-mm peripapillary scans in a single session using a Zeiss Cirrus HD-OCT 5000 with AngioPlex (Carl Zeiss Meditec). The Zeiss software (v11.0.0.29946) quantified measures of perfusion in the radial peripapillary capillary (RPC) plexus in 4 sectors (superior, nasal, inferior, temporal). The average of these sectors was calculated and reported.

Main outcome measures

Radial peripapillary capillary plexus perfusion was quantified using 2 parameters: capillary perfusion density (CPD) and capillary flux index (CFI). Intraclass correlation coefficients (ICCs) were used to quantify repeatability. For subjects who had both eyes included, the average values of each scan pair were used to assess interocular symmetry of CPD and CFI.

Results

Of 374 eyes, 46 were from participants who had AD, 85 were from participants who had MCI, 87 were from participants who had PD, and 156 were from participants who had normal cognition. Capillary perfusion density ICC in AD = 0.88 (95% confidence interval [CI], 0.79-0.93), MCI = 0.95 (0.92-0.96), PD = 0.91 (0.87-0.94), and controls = 0.90 (0.87-0.93). Capillary flux index ICC in AD = 0.82 (0.70-0.90), MCI = 0.87 (0.80-0.91), PD = 0.91 (0.87-0.94) and controls = 0.85 (0.79-0.89). There were no significant differences in interocular variation in average CPD and CFI in AD, MCI, or PD (all P > 0.05). Isolated interocular sectoral CPD differences were noted in AD (nasal, P = 0.049; temporal, P = 0.024), PD (nasal, P = 0.036), and controls (nasal, P = 0.016). Interocular differences in CFI in the superior sector in MCI (P = 0.028) and in average CFI for controls (P = 0.035) were observed.

Conclusions

Peripapillary OCTA repeatability in AD, MCI, and PD is good-excellent and similar to those with normal cognition. Insignificant interocular asymmetry in peripapillary OCTA suggests neurodegeneration may proceed uniformly; future studies may reveal the appropriateness of single-eye imaging.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1016/j.xops.2021.100075

Publication Info

Ma, Justin P, Cason B Robbins, Sandra S Stinnett, Kim G Johnson, Burton L Scott, Dilraj S Grewal and Sharon Fekrat (2021). Repeatability of Peripapillary OCT Angiography in Neurodegenerative Disease. Ophthalmology science, 1(4). p. 100075. 10.1016/j.xops.2021.100075 Retrieved from https://hdl.handle.net/10161/26948.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Stinnett

Sandra Sue Stinnett

Associate Professor of Biostatistics & Bioinformatics

Analysis of data for ophthalmology including observational studies and clinical trials. Assessment of reproducibility in grading measurements for ophthalmic studies. Teaching medical statistics.

Johnson

Kim G Johnson

Assistant Professor of Psychiatry and Behavioral Sciences
Scott

Burton Lasater Scott

Professor of Neurology

I am a Movement Disorders Neurologist and see patients at the Morreene Rd Clinic and at the Durham VA Medical Center.
Among the types of movement disorders patients that I see in clinic are individuals who have Parkinson's disease, Essential Tremor, tics, chorea, dystonia, Huntington's disease, tardive movement disorders and Wilson's disease. I use botulinum toxin injections to treat selected patients afflicted with dystonia, tremors, and tics. I manage patients who have undergone deep brain stimulation (DBS) for the treatment of Parkinson's disease, Essential Tremor,and dystonia. In addition to managing patients who have movement disorders, I participate in a variety of clinical trials focussed on improving the management and treatment of Parkinson's disease, Huntington's disease, and dystonia.

Key words: movement disorders, Parkinson's disease, tremors, tics, chorea, dystonia, botulinum toxin injections.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.